



1. Snapshot of Sequoya
2. The European Opportunity
3. Sequoya in 2020 - achieved
4. Sequoya in 2021 - planned



SNAPSHOT OF SEQUOYA

Across 2020: producer of highly refined cannabinoid extracts intended for use in formulas for various consumer goods products.

A Canadian company, registered in Ontario (Sequoia Cannabis Ltd.) with main operations in the heart of Europe – Poland (Sequoia Europe Ltd.).

2020

- Produce highly refined cannabinoid extracts - for use in cosmetics & supplements
- Sell refined extracts to brand manufacturers - Europe & Asia-Pacific
- Strength in vital Accreditation / Standards in line with incumbent industries, diversified products & custom formulas
- Many competitors proving unequipped & uncertified to supply maturing European market



GMP Food Grade certified, HACCP, Food Sanitation, Certified to produce for Cosmetics
Pre-Approved for THC Handling Permit

2021

- Q1: THC extracts – sales to Medical Marijuana Brands – mainly to German Market
- Q2: GMP Pharma grade certified – translates to supplying pharmaceutical Co.'s worldwide

Sequoia currently getting 2–4 inquiries weekly from companies worldwide, inquiring about pharma grade extracts from hemp & cannabis

DEVELOPED 8 PRODUCTS



(Pharma Grade Isolate)

Sequoia's Formula

Sequoia's Formula

Sequoia's Formula

EUROPE'S OPPORTUNITY: LEGAL CBD MARKET & EMERGING INDUSTRY



- CBD sales est. 450m € / EU 30% Global market share
- CBD use in retail products legal / Must be derived from hemp & THC is 0.2%
- Key industries: Cosmetics & Supplements – Strongest growth: Germany, Poland, Czech Rep., Spain, UK
- , HEMP ' or CBD products line shelves & isles of major chains in countries named above

Majors Coming to the Fore

- Big international consumer brands, Nestle, L'Oreal, Johnson & Johnson etc.
- Distribution via FMCG channels chains & across borders
- Many Brands Entering the market - Sequoya Plans to Establish a Leading Position as a Accredited Supplier of CBD


2021

- Emergence of: Pharmaceutical grade products, Medical Grade THC. Vape Products
- Distribution across pharmacies, in hospitals and medical marijuana distribution outlets



Poland Location Advantage

- Centrally located in Europe
- Currency is ¼ the Euro
- Rent is ¼ that the cost in Canada / Salaries are 1/3 the cost in Canada
- Offers deep science based talent pool
- / Sequoya was able to build an extremely talented talented team



2020 – PRODUCT DEVELOPMENT & INITIAL SALES LAUNCH

Products Development

(1st Pandemic lockdown)

Silver Lining - time used to advance Sequoia's competitive advantage


Sales Launch in August 2020

Monthly Sales CAD \$ 110,000.00

Reached break even in November

5 MONTHS TOTAL
(Year end)

CAD \$400,000



Clients & Profitability in 2020

Steady 12% sales increase month over month

Pipeline currently has 628,000€ in orders

/ Australian currency \$1,009,000

Average Sale Profit Margin: 64%

Overall Sequoia EBIT: 13%

Covid 1st wave

March to July

Covid 2nd wave

March to July

SEQUOYA IN 2021

Targets for 2021

- **Focus on further vital industry compliance & accreditation and moving further ahead of the competition**

- **Q1 2021 THC Extracts Processing Permit**

Already Pre-Approved for the THC Extract Process Permit
Leads to direct sales to pharma & medical MJ companies
Sequoia has limited competition in Europe
High margin sales, 250% margin

- **Q2 2021 EU GMP Pharma Certification**

Direct Sales to Pharma & Medical MJ Companies
Sequoia has very limited competition in Europe
Distribution worldwide
High margin sales, 600% - 800% margins

- **Q3 2021 ISO Cosmetics Certification**

- **Q4 2021 Good Laboratory Practice Certification**

- **Continue to expand CBD supply to cosmetics & supplements brands**

Sequoia's already highly refined CBD products, custom formulations & standards in line with target industries surpasses does not have an equal in Europe – Sequoia will continue to innovate & lead in standards

Sequoia Plans to Establish a
Leading Position as an
Accredited Supplier of CBD
To Consumer Goods
Manufacturers & Pharma
Companies across 2021

2021 Expanding to Primary Target Regions

EU Countries

Germany,
UK,
Spain,
Holland,
Poland,
Switzerland,
Luxembourg
Italy,
Ireland

Asia Pacific

Japan,
South Korea
China,
New Zealand
Australia



THANK YOU

Shemek Fedyczkowski : CEO

visit us at: www.sequoya.ca

